Why the study?
What are the pharmacokinetic properties of glycopyrrolate administered via intravenous, intramuscular, and oral routes?
What are the pharmacokinetic properties of glycopyrrolate administered via intravenous, intramuscular, and oral routes?
Oral administration of glycopyrrolate has low and variable absorption, making it unsuitable for routine premedication, whereas intramuscular administration provides fast and predictable absorption.
Answers are grounded in this paper and cite their sources.
May limit oral glycopyrrolate for premedication; leaves open optimal IM dosing in clinical settings.
In the present study, a sensitive and reproducible radioreceptor assay (RRA) was used to evaluate the basic pharmacokinetic properties of glycopyrrolate, a quaternary amine with peripheral antimuscarinic activity. Based on the plasma levels after a single intravenous injection, 6 micrograms/kg (n = 6), the distribution phase half-life (2.22 +/- 1.26 s.d. min) and the elimination phase half-life (0.83 +/- 0.29 h) of glycopyrrolate were short due to the low distribution volume during the elimination phase (0.64 +/- 0.29 l/kg) and to the respectively high total plasma clearance value (0.54 +/- 0.14 l/kg/h). An intramuscular injection, 8 micrograms/kg (n = 6), was followed by a fast and predictable systemic drug absorption and clinical effects (heart rate increase, dry mouth). In this group the time to maximum plasma concentration (tmax) was 27.48 +/- 6.12 min and the maximum plasma concentration (Cmax) was 3.47 +/- 1.48 micrograms/l. After oral drug intake, 4 mg (n = 6), an apparently low and variable gastrointestinal absorption was found (tmax = 300.0 +/- 197.2 min, Cmax = 0.76 +/- 0.35 microgram/l), thus indicating that the oral route of drug administration is of no value as a routine premedication. The correlation between the plasma concentration of glycopyrrolate and the drug effects appears to be variable. Because of its sensitivity, the RRA method proved to be quite useful in evaluating the kinetics of glycopyrrolate and its relationship to various clinical effects.
No takes yet. Share an insight, caveat, or question.
Ali‐Melkkilä et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: